

# Combination of DEL Screening and Computational Platform

Accelerating Results with Precision and Efficiency

 [XtalPi Application Note](#)

While DEL screening offers significant advantages, many users prefer virtual screening in the early stages of drug discovery due to speed and cost

### Massive Library Size

Enables simultaneous screening of billions of compounds, increasing the chances of finding novel hits

### Minimal Protein and Assay Requirements

Requires minimal target protein and assay development, making highly efficient and accessible for early-stage drug discovery

### Reduced False Positives

Yields more reliable results, reducing false positives compared to virtual screening

DEL  
Screening

Virtual  
Screening

### Speed

Conducted quickly without needing physical samples

### Cost-Effectiveness

Narrows compound candidates with low cost before moving to more resource-intensive methods

# XtalPi Combines DEL Library Screening with its Proprietary Computational Platform to Accelerate the Screening Process, Maximize Efficiency & Lower Cost

## DEL Screening

- **Screens** massive compound libraries **simultaneously**
- Requires **minimal** target protein
- **Reduces** false positive


## The XtalPi Difference

## Computational Platform

- **Lowers** the number of compounds to be synthesized
- Serves an **additional validation** step for accuracy

**Accelerates** the screening process  
**Maximizes** resource efficiency  
**Lowers** synthesis costs


# DEL Screening Combined with the Computational Platform Reduces Time and Resources Without Compromising Accuracy



# Project-Specific Assessments to Confirm DEL Affinity Selection Conditions


## Non-targeting control

DEL compounds were incubated with beads without the immobilized target.




## Target only





DEL molecules were incubated with the target immobilized on beads.



## Target with ligand

A known ligand binds to the immobilized PPI target on beads before incubation with DEL compounds.



-  Beads
-  DEL molecules
-  Protein of interest
-  Known ligand of the protein

**Other selection conditions** can also be tailored and designed to best identify potential target binders

Submitted in Parallel to  
Next-Generation Sequencing


# Hit Screening via DEL Affinity Selection and NGS Identified Active Compounds with High Speed and Throughput

## Several Rounds of DEL Affinity Selection




### a. Library Incubation

Incubate the PPI-like target with XtalPi's exclusive 3- and 4-cycle DEL, containing over 100 billion DNA-encoded compounds



### b. Wash



### c. Elution

## Next Generation Sequencing




Send for next-generation sequencing (NGS) of their DNA tags

## Identifying Building Block Structures and Selecting Potential Positive Binders

### Positive Binders


Ready for XtalPi Computational Platform

NGS data deconvoluted to identify building blocks and select potential positive binders for computational screening based on enrichment patterns, suggesting high target affinity



# Computational Platform Reduces the Time and Cost of Potent Hit Identification by Recommending Optimal Compounds

## Docking Pose Analysis and Free Energy Perturbation (FEP) Calculations



### XPose

Receptor-ligand binding pose prediction software analyzes docking poses of selected DEL screening compounds using interaction fingerprints (IFP).

### XFEP


Click [here](#) to learn more about XFEP application in drug discovery

FEP calculation software employs a proprietary force field to predict FEP for compounds with the best binding poses.

Calculated binding free energies identify compounds with the highest predicted target affinity for automated off-DNA synthesis and validation.

The XtalPi Computational Platform **reduces** time to **~ 2 weeks**, narrowing the selection to a **few compounds for synthesis**.

# Combination of DEL Screening with XtalPi's Computational Platform Accelerates the Screening Process, Maximizes Efficiency, and Ensures Accuracy



- Combination of DEL and Computational Platform **reduces** the **number of synthesized compounds** and **time** while **ensuring accuracy** and **quality**



## Cost-Effective Screening

Leverages DEL technology to rapidly screen billions of compounds at a **fraction of the cost** of physical screening




## Efficient Selection by Computation-Driven Prediction

Facilitates the synthesis of only handful compounds to reduce time and resources

Also offer Automated Synthesis and In-house Biology Assay Platform to streamline and accelerate drug discovery process.

Please click [here](#) if you want to learn more about our [automated synthesis](#) and [in-house biology platform](#)





# Contact Us for More Information



 [bd@xtalpi-mail.com](mailto:bd@xtalpi-mail.com)

 [www.xtalpi.com/en](http://www.xtalpi.com/en)